Charles Schwab Investment Management Inc. Raises Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Charles Schwab Investment Management Inc. grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 7.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,796,838 shares of the company’s stock after acquiring an additional 129,416 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Hims & Hers Health were worth $43,448,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after purchasing an additional 1,508 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter worth approximately $48,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of HIMS opened at $33.10 on Friday. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The company has a market cap of $7.35 billion, a P/E ratio of 75.24 and a beta of 1.37. The firm has a 50 day simple moving average of $38.49 and a two-hundred day simple moving average of $28.04.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on HIMS shares. Leerink Partners raised their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Piper Sandler lifted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Bank of America reissued an “underperform” rating and set a $21.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Finally, TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $37.23.

Insider Activity

In related news, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the completion of the sale, the chief executive officer now owns 109,956 shares in the company, valued at $3,256,896.72. This represents a 41.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 969,191 shares of company stock worth $34,005,375. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.